Pedro Nazareth Aguiar

Pedro Nazareth Aguiar

Auto-generated profile, based on publicly available information

Pedro Nazareth Aguiar

Faculdade de Medicina do ABC, Santo André, SP, Brazil

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 May 2017 in Immunotherapy
Verified
Journal Article
Closed access
PAPedro N Aguiar
Pedro N Aguiar
Ramon Andrade Bezerra De MelloRamon Andrade Bezerra De Mello
Ramon Andrade Bezerra De Mello
PHPeter Hall
Peter Hall
HTHakaru Tadokoro
Hakaru Tadokoro
GLGilberto de Lima Lopes
Gilberto de Lima Lopes
Aim: The treatment of non-small-cell lung cancer has changed after the development of the immune checkpoint inhibitors. Although the most studied biomarker is PD-L1 expression, its clinical significance is still debatable. In this article, we show the updated survival analysis of all published data. Methods: We searched in network and conference data sources for relevant clinical studies of immunotherapy for non-small-cell lung cancer that assessed the PD-L1 expression even as an exploratory analysis. The updated survival hazard ratios (HR) were included in the analysis. Results: 14 studies with 2857 patients were included (2019 treated with immunotherapy). The response rate was as higher among PD-L1-positive patients (RR: 2.19, 95% CI: 1.63–2.94). PD-L1 expression was also related to better progression-free survival (HR: 0.69, 95% CI: 0.57–0.85) and better overall survival (HR: 0.77, 95% CI: 0.67–0.89). Conclusion: PD-L1 overexpression predicts activity as well as better survival for patients treated wit...

14 March 2016 in Immunotherapy
Verified
Journal Article
Closed access
PAPedro N Aguiar
Pedro N Aguiar
ISIlka Lopes Santoro
Ilka Lopes Santoro
HTHakaru Tadokoro
Hakaru Tadokoro
GLGilberto de Lima Lopes
Gilberto de Lima Lopes
BFBruno Andraus Filardi
Bruno Andraus Filardi
Ramon Andrade Bezerra De MelloRamon Andrade Bezerra De Mello
Ramon Andrade Bezerra De Mello
Background: Tumor programmed death ligand one (PD-L1) expression has been studied in several trials in non-small-cell lung cancer. Methods: We assessed the potential role of PD-L1 expression according to Cochrane Collaboration's Guidelines. Results: 13 studies with 1979 patients were included. Among 915 PD-L1 negative patients this rate was 13% (RR 2.08; 95% CI: 1.49–2.91; p < 0.01). The response rate has increased concurrent to the PD-L1 expression (Pearson's correlation, r = 0.43). PD-L1 expression was also related to better 24-weeks progression-free rate (RR 0.79; 95% CI: 0.71–0.89) and a trend toward better 1-year overall survival rate (RR 0.96; 95% CI: 0.87–1.06). Conclusion: Taking this data in account, PD-L1 overexpression could not be currently considered a robust biomarker to tailor the immune checkpoint inhibitors treatment.

15 June 2017 in Annals of Oncology
Verified
Journal Article
Closed access
PDF file
PAP. N. Aguiar
P. N. Aguiar
LPL A Perry
L A Perry
JPJ. Penny-Dimri
J. Penny-Dimri
HMHani Babiker, MD
Hani Babiker, MD
HTH. Tadokoro
H. Tadokoro
Gilberto De Lima LopesGilberto De Lima Lopes
Gilberto De Lima Lopes
Immune checkpoint inhibitors improve outcomes compared with chemotherapy in lung cancer. Tumor PD-L1 receptor expression is being studied as a predictive biomarker. The objective of this study was to assess the cost-effectiveness and economic impact of second-line treatment with nivolumab, pembrolizumab, and atezolizumab with and without the use of PD-L1 testing for patient selection. We developed a decision-analytic model to determine the cost-effectiveness of PD-L1 assessment and second-line immunotherapy versus docetaxel. The model used outcomes data from randomized clinical trials (RCTs) and drug acquisition costs from the United States. Thereafter, we used epidemiologic data to estimate the economic impact of the treatment. We included four RCTs (2 with nivolumab, 1 with pembrolizumab, and 1 with atezolizumab). The incremental quality-adjusted life year (QALY) for nivolumab was 0.417 among squamous tumors and 0.287 among non-squamous tumors and the incremental cost-effectiveness ratio (ICER) were $155 605 and $187 685, respectively. The QALY gain in the base case for atezolizumab was 0.354 and the ICER was $215 802. Compared with treating all patients, the selection of patients by PD-L1 expression improved incremental QALY by up to 183% and decreased the ICER by up to 65%. Pembrolizumab was studied only in patients whose tumors expressed PD-L1. The QALY gain was 0.346 and the ICER was $98 421. Patient selection also reduced the budget impact of immunotherapy. The use of PD-L1 expression as a biomarker increases cost-effectiveness of immunotherapy but also diminishes the number of potential life-years saved.

1 January 2017 in ESMO Open
Verified
Journal Article
Open access
PDF file
PAPedro Nazareth Aguiar
Pedro Nazareth Aguiar
Ramon Andrade Bezerra De MelloRamon Andrade Bezerra De Mello
Ramon Andrade Bezerra De Mello
CBCarme Lia Maria Noia Barreto
Carme Lia Maria Noia Barreto
LPLuke Alastair Perry
Luke Alastair Perry
JPJahan Penny-Dimri
Jahan Penny-Dimri
GLGilberto de Lima Lopes
Gilberto de Lima Lopes
Lung cancer is the leading cause of cancer-related deaths in the world. Immune checkpoint inhibitors (ICI) stimulate cytotoxic lymphocyte activity against tumour cells. These agents are available for the treatment of non-small cell lung cancer (NSCLC) after failure of platinum-based therapy. One recent study has demonstrated that ICI monotherapy was superior to platinum-based chemotherapy for first-line treatment. Nevertheless, this benefit was only for a minority of the population (30%) whose tumour programmed death receptor ligand-1 (PD-L1) expression was above 50%. Therefore, several strategies are under investigation. One option for patients with PD-L1 expression lower than 50% may be the combination of ICI with platinum-based chemotherapy or with ICIs against different targets. However, all of these combinations are at an early stage of investigation and may be very expensive or toxic, producing several harmful adverse events.


3 August 2016 in Immunotherapy
Verified
Journal Article
Closed access
PAPedro N Aguiar
Pedro N Aguiar
ISIlka Lopes Santoro
Ilka Lopes Santoro
HTHakaru Tadokoro
Hakaru Tadokoro
GLGilberto de Lima Lopes
Gilberto de Lima Lopes
BFBruno Andraus Filardi
Bruno Andraus Filardi
Ramon Andrade Bezerra De MelloRamon Andrade Bezerra De Mello
Ramon Andrade Bezerra De Mello
Background: Recent studies with nivolumab (a monoclonal antibody against programmed cell death 1 [PD-1] receptor) have shown promise non-small-cell lung cancer (NSCLC) treatment. Methods: To review available clinical trials data in order to assess nivolumab efficacy and the role of tumoral PDL-1 expression as a biomarker. Results: Nine eligible studies included 2102 patients. In the second line setting, nivolumab achieved a 1-year survival rate of 41%; and in the first line, a 1-year survival rate of 76%. For those with PD-L1 expression <1%, nivolumab showed a trend for improved survival compared with docetaxel. Conclusions: The available data reinforce nivolumab activity against NSCLC in first-line or subsequent lines. Although PD-L1 expression is related to greater response, PD-L1 negative patients had also some benefit.